{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T16:24:32Z","timestamp":1793118272859,"version":"4.5.0"},"reference-count":115,"publisher":"The Endocrine Society","issue":"12","license":[{"start":{"date-parts":[[2022,10,5]],"date-time":"2022-10-05T00:00:00Z","timestamp":1664928000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,11,25]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The concept of using a targeting molecule labeled with a diagnostic radionuclide for using positron emission tomography or single photon emission computed tomography imaging with the potential to demonstrate that tumoricidal radiation can be delivered to tumoral sites by administration of the same or a similar targeting molecule labeled with a therapeutic radionuclide termed \u201ctheranostics.\u201d Peptide receptor radionuclide therapy (PRRT) with radiolabeled somatostatin analogs (SSAs) is a well-established second\/third-line theranostic treatment for somatostatin receptor-positive well-differentiated (neuro-)endocrine neoplasms (NENs). PRRT with 177Lu-DOTATATE was approved by the regulatory authorities in 2017 and 2018 for selected patients with low-grade well-differentiated gastroenteropancreatic (GEP) NENs. It improves progression-free survival as well as quality of life of GEP NEN patients. Favorable symptomatic and biochemical responses using PRRT with 177Lu-DOTATATE have also been reported in patients with functioning metastatic GEP NENs like metastatic insulinomas, Verner Morrison syndromes (VIPomas), glucagonomas, and gastrinomas and patients with carcinoid syndrome. This therapy might also become a valuable therapeutic option for inoperable low-grade bronchopulmonary NENs, inoperable or progressive pheochromocytomas and paragangliomas, and medullary thyroid carcinomas. First-line PRRT with 177Lu-DOTATATE and combinations of this therapy with cytotoxic drugs are currently under investigation. New radiolabeled somatostatin receptor ligands include SSAs coupled with alpha radiation emitting radionuclides and somatostatin receptor antagonists coupled with radionuclides.<\/jats:p>","DOI":"10.1210\/clinem\/dgac574","type":"journal-article","created":{"date-parts":[[2022,10,5]],"date-time":"2022-10-05T18:19:11Z","timestamp":1664993951000},"page":"3199-3208","source":"Crossref","is-referenced-by-count":51,"title":["Peptide Receptor Radionuclide Therapy"],"prefix":"10.1210","volume":"107","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0679-6209","authenticated-orcid":false,"given":"Johannes","family":"Hofland","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Section of Endocrinology, ENETS Center of Excellence, Erasmus MC and Erasmus Cancer Institute , Rotterdam , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8000-6490","authenticated-orcid":false,"given":"Tessa","family":"Brabander","sequence":"additional","affiliation":[{"name":"Department of Radiology & Nuclear Medicine, ENETS Center of Excellence, Erasmus MC and Erasmus Cancer Institute , Rotterdam , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1401-1993","authenticated-orcid":false,"given":"Frederik A","family":"Verburg","sequence":"additional","affiliation":[{"name":"Department of Radiology & Nuclear Medicine, ENETS Center of Excellence, Erasmus MC and Erasmus Cancer Institute , Rotterdam , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2319-391X","authenticated-orcid":false,"given":"Richard A","family":"Feelders","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Section of Endocrinology, ENETS Center of Excellence, Erasmus MC and Erasmus Cancer Institute , Rotterdam , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1463-5165","authenticated-orcid":false,"given":"Wouter W","family":"de Herder","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Section of Endocrinology, ENETS Center of Excellence, Erasmus MC and Erasmus Cancer Institute , Rotterdam , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2022,10,5]]},"reference":[{"issue":"(2)","key":"2022112511293689000_dgac574-B1","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1210\/endrev\/bnz004","article-title":"Advances in the diagnosis and management of well-differentiated neuroendocrine neoplasms","volume":"41","author":"Hofland","year":"2020","journal-title":"Endocr Rev"},{"key":"2022112511293689000_dgac574-B2","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.ejca.2021.01.008","article-title":"Consensus on molecular imaging and theranostics in neuroendocrine neoplasms","volume":"146","author":"Ambrosini","year":"2021","journal-title":"Eur J Cancer"},{"issue":"(2)","key":"2022112511293689000_dgac574-B3","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1001\/jama.1946.02870190005002","article-title":"Radioactive iodine in the study of thyroid physiology; the use of radioactive iodine therapy in hyperthyroidism","volume":"131","author":"Hertz","year":"1946","journal-title":"J Am Med Assoc"},{"issue":"(1)","key":"2022112511293689000_dgac574-B4","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1056\/NEJM198107023050103","article-title":"Scintigraphic localization of pheochromocytoma","volume":"305","author":"Sisson","year":"1981","journal-title":"N Engl J Med"},{"issue":"(1)","key":"2022112511293689000_dgac574-B5","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1111\/j.1749-6632.1994.tb17300.x","article-title":"Radiotherapy with a radiolabeled somatostatin analogue, [111In-DTPA-D-Phe1]-octreotide. A case history","volume":"733","author":"Krenning","year":"1994","journal-title":"Ann N Y Acad Sci"},{"issue":"(11)","key":"2022112511293689000_dgac574-B6","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1007\/s002590050476","article-title":"Yttrium-90 DOTATOC: first clinical results","volume":"26","author":"Otte","year":"1999","journal-title":"Eur J Nucl Med"},{"issue":"(6)","key":"2022112511293689000_dgac574-B7","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1089\/cbr.1999.14.477","article-title":"Receptor-mediated radionuclide therapy with 90Y-DOTA-D-Phe1-Tyr3-Octreotide: preliminary report in cancer patients","volume":"14","author":"Paganelli","year":"1999","journal-title":"Cancer Biother Radiopharm"},{"issue":"(9)","key":"2022112511293689000_dgac574-B8","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1007\/s002590100574","article-title":"[177Lu-DOTAOTyr3]octreotate: comparison with [111In-DTPAo]octreotide in patients","volume":"28","author":"Kwekkeboom","year":"2001","journal-title":"Eur J Nucl Med"},{"issue":"(2)","key":"2022112511293689000_dgac574-B9","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 trial of (177)Lu-dotatate for midgut neuroendocrine tumors","volume":"376","author":"Strosberg","year":"2017","journal-title":"N Engl J Med"},{"issue":"(3)","key":"2022112511293689000_dgac574-B10","doi-asserted-by":"publisher","first-page":"114","DOI":"10.3390\/ph12030114","article-title":"Lutathera(\u00ae): the first FDA- and EMA-approved radiopharmaceutical for peptide receptor radionuclide therapy","volume":"12","author":"Hennrich","year":"2019","journal-title":"Pharmaceuticals (Basel)"},{"issue":"(16)","key":"2022112511293689000_dgac574-B11","doi-asserted-by":"publisher","first-page":"4617","DOI":"10.1158\/1078-0432.CCR-16-2743","article-title":"Long-term efficacy, survival, and safety of [(177)Lu-DOTA(0), Tyr(3)]octreotate in patients with gastroenteropancreatic and bronchial neuroendocrine tumors","volume":"23","author":"Brabander","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"(3)","key":"2022112511293689000_dgac574-B12","doi-asserted-by":"publisher","first-page":"584","DOI":"10.3390\/cancers14030584","article-title":"Peptide receptor radionuclide therapy with [(177)Lu]Lu-DOTA-TATE in patients with advanced GEP NENS: present and future directions","volume":"14","author":"Del Olmo-Garc\u00eda","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"(4)","key":"2022112511293689000_dgac574-B13","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.3390\/cancers14041055","article-title":"Radiolabeled somatostatin analogues for diagnosis and treatment of neuroendocrine tumors","volume":"14","author":"Ambrosini","year":"2022","journal-title":"Cancers (Basel)"},{"key":"2022112511293689000_dgac574-B14","doi-asserted-by":"publisher","first-page":"861434","DOI":"10.3389\/fendo.2022.861434","article-title":"New insights in PRRT: lessons from 2021","volume":"13","author":"Puliani","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"(4)","key":"2022112511293689000_dgac574-B15","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1007\/s11912-021-01037-7","article-title":"Strategies towards improving clinical outcomes of peptide receptor radionuclide therapy","volume":"23","author":"Minczeles","year":"2021","journal-title":"Curr Oncol Rep"},{"issue":"(24)","key":"2022112511293689000_dgac574-B16","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1056\/NEJM198312153092406","article-title":"Somatostatin","volume":"309","author":"Reichlin","year":"1983","journal-title":"N Engl J Med"},{"issue":"(25)","key":"2022112511293689000_dgac574-B17","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1056\/NEJM198312223092506","article-title":"Somatostatin","volume":"309","author":"Reichlin","year":"1983","journal-title":"N Engl J Med"},{"issue":"(4)","key":"2022112511293689000_dgac574-B18","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1124\/pr.117.015388","article-title":"International Union of Basic and Clinical Pharmacology. CV. Somatostatin receptors: structure, function, ligands, and new nomenclature","volume":"70","author":"G\u00fcnther","year":"2018","journal-title":"Pharmacol Rev"},{"issue":"(18)","key":"2022112511293689000_dgac574-B19","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.1001\/jama.1985.03350420155035","article-title":"Somatostatin receptors","volume":"253","author":"Maurer","year":"1985","journal-title":"JAMA"},{"issue":"(6)","key":"2022112511293689000_dgac574-B20","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1210\/jcem-65-6-1127","article-title":"Hormone-producing gastrointestinal tumors contain a high density of somatostatin receptors","volume":"65","author":"Reubi","year":"1987","journal-title":"J Clin Endocrinol Metab"},{"key":"2022112511293689000_dgac574-B21","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1159\/000074662","article-title":"Somatostatin receptors in pheochromocytoma","volume":"31","author":"de Herder","year":"2004","journal-title":"Front Horm Res"},{"issue":"(4)","key":"2022112511293689000_dgac574-B22","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1677\/erc.0.0100451","article-title":"Somatostatin receptors in gastroentero-pancreatic neuroendocrine tumours","volume":"10","author":"de Herder","year":"2003","journal-title":"Endocr Relat Cancer"},{"issue":"(1)","key":"2022112511293689000_dgac574-B23","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1210\/er.2000-0001","article-title":"The pathophysiological consequences of somatostatin receptor internalization and resistance","volume":"24","author":"Hofland","year":"2003","journal-title":"Endocr Rev"},{"issue":"(12)","key":"2022112511293689000_dgac574-B24","doi-asserted-by":"publisher","first-page":"e4903","DOI":"10.1210\/clinem\/dgab588","article-title":"Metastatic medullary thyroid cancer: the role of 68Gallium-DOTA-somatostatin analogue PET\/CT and peptide receptor radionuclide therapy","volume":"106","author":"Hayes","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"(3)","key":"2022112511293689000_dgac574-B25","doi-asserted-by":"publisher","first-page":"R145","DOI":"10.1530\/ERC-18-0495","article-title":"Management of carcinoid syndrome: a systematic review and meta-analysis","volume":"26","author":"Hofland","year":"2019","journal-title":"Endocr Relat Cancer"},{"issue":"(18)","key":"2022112511293689000_dgac574-B26","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1056\/NEJM199011013231805","article-title":"Somatostatin-receptor imaging in the localization of endocrine tumors","volume":"323","author":"Lamberts","year":"1990","journal-title":"N Engl J Med"},{"issue":"(2)","key":"2022112511293689000_dgac574-B27","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1159\/000225946","article-title":"ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: somatostatin receptor imaging with (111)In-pentetreotide","volume":"90","author":"Kwekkeboom","year":"2009","journal-title":"Neuroendocrinology"},{"issue":"(Suppl 1)","key":"2022112511293689000_dgac574-B28","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1159\/000201398","article-title":"Somatostatin receptor: scintigraphy and radionuclide therapy","volume":"57","author":"Krenning","year":"1996","journal-title":"Digestion"},{"issue":"(3)","key":"2022112511293689000_dgac574-B29","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s11102-006-0270-5","article-title":"Somatostatin receptor imaging for neuroendocrine tumors","volume":"9","author":"de Herder","year":"2006","journal-title":"Pituitary"},{"issue":"(3)","key":"2022112511293689000_dgac574-B30","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1159\/000471879","article-title":"ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: radiological, nuclear medicine and hybrid imaging","volume":"105","author":"Sundin","year":"2017","journal-title":"Neuroendocrinology"},{"issue":"(11)","key":"2022112511293689000_dgac574-B31","doi-asserted-by":"publisher","first-page":"R627","DOI":"10.1530\/ERC-19-0165","article-title":"Molecular imaging and radionuclide therapy of pheochromocytoma and paraganglioma in the era of genomic characterization of disease subgroups","volume":"26","author":"Ta\u00efeb","year":"2019","journal-title":"Endocr Relat Cancer"},{"issue":"(7)","key":"2022112511293689000_dgac574-B32","doi-asserted-by":"publisher","first-page":"e2662","DOI":"10.1210\/clinem\/dgac207","article-title":"Molecular imaging of neuroendocrine neoplasms","volume":"107","author":"Refardt","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"(12)","key":"2022112511293689000_dgac574-B33","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1016\/S1470-2045(21)00572-6","article-title":"(177)Lu-dotatate plus long-acting octreotide versus high-dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial","volume":"22","author":"Strosberg","year":"2021","journal-title":"Lancet Oncol"},{"issue":"(11)","key":"2022112511293689000_dgac574-B34","doi-asserted-by":"publisher","first-page":"2182","DOI":"10.1002\/cncr.34191","article-title":"Long-term survival and toxicity in patients with neuroendocrine tumors treated with (177) Lu-octreotate peptide radionuclide therapy","volume":"128","author":"Kennedy","year":"2022","journal-title":"Cancer"},{"issue":"(3)","key":"2022112511293689000_dgac574-B35","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/s00259-015-3193-4","article-title":"Subacute haematotoxicity after PRRT with (177)Lu-DOTA-octreotate: prognostic factors, incidence and course","volume":"43","author":"Bergsma","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"(3)","key":"2022112511293689000_dgac574-B36","doi-asserted-by":"publisher","first-page":"452","DOI":"10.2967\/jnumed.117.189712","article-title":"Persistent hematologic dysfunction after peptide receptor radionuclide therapy with (177)Lu-DOTATATE: incidence, course, and predicting factors in patients with gastroenteropancreatic neuroendocrine tumors","volume":"59","author":"Bergsma","year":"2018","journal-title":"J Nucl Med"},{"issue":"(5)","key":"2022112511293689000_dgac574-B37","doi-asserted-by":"publisher","first-page":"L17","DOI":"10.1530\/ERC-15-0543","article-title":"High risk of myelodysplastic syndrome and acute myeloid leukemia after 177Lu-octreotate PRRT in NET patients heavily pretreated with alkylating chemotherapy","volume":"23","author":"Brieau","year":"2016","journal-title":"Endocr Relat Cancer"},{"issue":"(6)","key":"2022112511293689000_dgac574-B38","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1097\/RLU.0000000000004182","article-title":"ACR-ACNM-ASTRO-SNMMI practice parameter for lutetium-177 (Lu-177) DOTATATE therapy","volume":"47","author":"Love","year":"2022","journal-title":"Clin Nucl Med"},{"issue":"(3)","key":"2022112511293689000_dgac574-B39","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1159\/000475526","article-title":"ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasia: peptide receptor radionuclide therapy with radiolabeled somatostatin analogues","volume":"105","author":"Hicks","year":"2017","journal-title":"Neuroendocrinology"},{"issue":"(7)","key":"2022112511293689000_dgac574-B40","doi-asserted-by":"publisher","first-page":"937","DOI":"10.2967\/jnumed.118.230607","article-title":"NANETS\/SNMMI procedure standard for somatostatin receptor-based peptide receptor radionuclide therapy with (177)Lu-DOTATATE","volume":"60","author":"Hope","year":"2019","journal-title":"J Nucl Med"},{"issue":"(2)","key":"2022112511293689000_dgac574-B41","doi-asserted-by":"publisher","first-page":"222","DOI":"10.2967\/jnumed.119.240911","article-title":"NANETS\/SNMMI consensus statement on patient selection and appropriate use of (177)Lu-DOTATATE peptide receptor radionuclide therapy","volume":"61","author":"Hope","year":"2020","journal-title":"J Nucl Med"},{"issue":"(12)","key":"2022112511293689000_dgac574-B42","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1097\/MNM.0000000000001103","article-title":"177Lu-DOTATATE peptide receptor radionuclide therapy versus everolimus in advanced pancreatic neuroendocrine tumors: a systematic review and meta-analysis","volume":"40","author":"Satapathy","year":"2019","journal-title":"Nucl Med Commun"},{"issue":"(2)","key":"2022112511293689000_dgac574-B43","doi-asserted-by":"publisher","first-page":"e220290","DOI":"10.1001\/jamanetworkopen.2022.0290","article-title":"Association of upfront peptide receptor radionuclide therapy with progression-free survival among patients with enteropancreatic neuroendocrine tumors","volume":"5","author":"Pusceddu","year":"2022","journal-title":"JAMA Netw Open"},{"key":"2022112511293689000_dgac574-B44","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.ejcsup.2021.06.002","article-title":"Matching-adjusted indirect treatment comparison of [(177)Lu]Lu-DOTA-TATE, everolimus and sunitinib in advanced, unresectable gastroenteropancreatic neuroendocrine tumours: relative effectiveness of [(177)Lu]Lu-DOTA-TATE in gastroenteropancreatic neuroendocrine tumours","volume":"16","author":"Khan","year":"2021","journal-title":"EJC Suppl"},{"issue":"(2)","key":"2022112511293689000_dgac574-B45","doi-asserted-by":"publisher","first-page":"358","DOI":"10.3390\/cancers13020358","article-title":"Treatment of advanced gastro-entero-pancreatic neuro-endocrine tumors: a systematic review and network meta-analysis of phase III randomized controlled trials","volume":"13","author":"Ricci","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"(6)","key":"2022112511293689000_dgac574-B46","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1007\/s00259-022-05727-7","article-title":"EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands","volume":"49","author":"Gleisner K","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2022112511293689000_dgac574-B47","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.122.263856","article-title":"Long-term outcomes of submaximal activities of peptide receptor radionuclide therapy with (177)Lu-DOTATATE in neuroendocrine tumour patients","author":"Minczeles","journal-title":"J Nucl Med"},{"issue":"(3)","key":"2022112511293689000_dgac574-B48","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1007\/s00259-018-4158-1","article-title":"Salvage peptide receptor radionuclide therapy with [(177)Lu-DOTA, Tyr(3)]octreotate in patients with bronchial and gastroenteropancreatic neuroendocrine tumours","volume":"46","author":"van der Zwan","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"(9)","key":"2022112511293689000_dgac574-B49","doi-asserted-by":"publisher","first-page":"3278","DOI":"10.1210\/jc.2017-00816","article-title":"Efficacy of peptide receptor radionuclide therapy for functional metastatic paraganglioma and pheochromocytoma","volume":"102","author":"Kong","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"issue":"(6)","key":"2022112511293689000_dgac574-B50","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1111\/cen.14106","article-title":"Peptide receptor radionuclide therapy in the management of advanced pheochromocytoma and paraganglioma: a systematic review and meta-analysis","volume":"91","author":"Satapathy","year":"2019","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"(1)","key":"2022112511293689000_dgac574-B51","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1530\/EJE-18-0901","article-title":"Treatment of inoperable or metastatic paragangliomas and pheochromocytomas with peptide receptor radionuclide therapy using 177Lu-DOTATATE","volume":"181","author":"Zandee","year":"2019","journal-title":"Eur J Endocrinol"},{"issue":"(1)","key":"2022112511293689000_dgac574-B52","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1186\/s12885-019-5540-5","article-title":"Peptide receptor radionuclide therapy in patients with medullary thyroid carcinoma: predictors and pitfalls","volume":"19","author":"Beukhof","year":"2019","journal-title":"BMC Cancer"},{"issue":"(9)","key":"2022112511293689000_dgac574-B53","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.2967\/jnumed.111.087932","article-title":"Quality of life in 265 patients with gastroenteropancreatic or bronchial neuroendocrine tumors treated with [177Lu-DOTA0, Tyr3]octreotate","volume":"52","author":"Khan","year":"2011","journal-title":"J Nucl Med"},{"issue":"(6)","key":"2022112511293689000_dgac574-B54","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1097\/RLU.0000000000001629","article-title":"Peptide receptor radionuclide therapy with 177Lu-octreotate in patients with somatostatin receptor expressing neuroendocrine tumors: six years\u2019 Assessment","volume":"42","author":"Hamiditabar","year":"2017","journal-title":"Clin Nucl Med"},{"issue":"(25)","key":"2022112511293689000_dgac574-B55","doi-asserted-by":"publisher","first-page":"2578","DOI":"10.1200\/JCO.2018.78.5865","article-title":"Health-related quality of life in patients with progressive midgut neuroendocrine tumors treated with (177)Lu-Dotatate in the phase III NETTER-1 trial","volume":"36","author":"Strosberg","year":"2018","journal-title":"J Clin Oncol"},{"issue":"(2)","key":"2022112511293689000_dgac574-B56","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1007\/s00259-017-3821-2","article-title":"Peptide receptor radionuclide therapy (PRRT) in European Neuroendocrine Tumour Society (ENETS) grade 3 (G3) neuroendocrine neoplasia (NEN)\u2014a single-institution retrospective analysis","volume":"45","author":"Thang","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"(2)","key":"2022112511293689000_dgac574-B57","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1530\/ERC-18-0424","article-title":"Peptide receptor radionuclide therapy in gastroenteropancreatic NEN G3: a multicenter cohort study","volume":"26","author":"Carlsen","year":"2019","journal-title":"Endocr Relat Cancer"},{"issue":"(3)","key":"2022112511293689000_dgac574-B58","doi-asserted-by":"publisher","first-page":"R67","DOI":"10.1530\/ERC-19-0400","article-title":"PRRT In high-grade gastroenteropancreatic neuroendocrine neoplasms (WHO G3)","volume":"27","author":"Sorbye","year":"2020","journal-title":"Endocr Relat Cancer"},{"issue":"(9)","key":"2022112511293689000_dgac574-B59","doi-asserted-by":"publisher","first-page":"3203","DOI":"10.1007\/s00259-022-05734-8","article-title":"Induction therapy with (177)Lu-DOTATATE procures long-term survival in locally advanced or oligometastatic pancreatic neuroendocrine neoplasm patients","volume":"49","author":"Minczeles","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"(4)","key":"2022112511293689000_dgac574-B60","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/j.surg.2017.11.007","article-title":"Peptide receptor radionuclide therapy as neoadjuvant therapy for resectable or potentially resectable pancreatic neuroendocrine neoplasms","volume":"163","author":"Partelli","year":"2018","journal-title":"Surgery."},{"issue":"(11)","key":"2022112511293689000_dgac574-B61","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.2967\/jnumed.115.158899","article-title":"Neoadjuvant treatment of nonfunctioning pancreatic neuroendocrine tumors with [177Lu-DOTA0, Tyr3]Octreotate","volume":"56","author":"van Vliet","year":"2015","journal-title":"J Nucl Med"},{"issue":"(4)","key":"2022112511293689000_dgac574-B62","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1210\/jc.2018-01991","article-title":"Symptomatic and radiological response to 177Lu-DOTATATE for the treatment of functioning pancreatic neuroendocrine tumors","volume":"104","author":"Zandee","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"(9)","key":"2022112511293689000_dgac574-B63","doi-asserted-by":"publisher","first-page":"e3665","DOI":"10.1210\/clinem\/dgab289","article-title":"Peptide receptor radionuclide therapy with 177Lu-DOTATATE for symptomatic control of refractory carcinoid syndrome","volume":"106","author":"Zandee","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"(7)","key":"2022112511293689000_dgac574-B64","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1097\/RLU.0000000000004203","article-title":"Dose-limiting bone marrow toxicities after peptide receptor radionuclide therapy are more prevalent in women than in men","volume":"47","author":"Minczeles","year":"2022","journal-title":"Clin Nucl Med"},{"issue":"(4)","key":"2022112511293689000_dgac574-B65","doi-asserted-by":"publisher","first-page":"e13088","DOI":"10.1111\/jne.13088","article-title":"Treatment of neuroendocrine tumours with (177) Lu-peptide receptor radionuclide therapy: challenging clinical scenarios and their management","volume":"34","author":"Navalkissoor","year":"2022","journal-title":"J Neuroendocrinol"},{"issue":"(4)","key":"2022112511293689000_dgac574-B66","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1007\/s00259-007-0691-z","article-title":"Hormonal crises following receptor radionuclide therapy with the radiolabeled somatostatin analogue [177Lu-DOTA0, Tyr3]octreotate","volume":"35","author":"de Keizer","year":"2008","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"(3)","key":"2022112511293689000_dgac574-B67","doi-asserted-by":"publisher","first-page":"443","DOI":"10.3390\/cancers13030443","article-title":"Evolution of the mesenteric mass in small intestinal neuroendocrine tumours","volume":"13","author":"Bla\u017eevi\u0107","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"(3)","key":"2022112511293689000_dgac574-B68","doi-asserted-by":"publisher","first-page":"R115","DOI":"10.1530\/ERC-17-0380","article-title":"Small intestinal neuroendocrine tumours and fibrosis: an entangled conundrum","volume":"25","author":"Blazevic","year":"2018","journal-title":"Endocr Relat Cancer"},{"issue":"(6)","key":"2022112511293689000_dgac574-B69","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1159\/000503144","article-title":"Peritoneal carcinomatosis in gastro-entero-pancreatic neuroendocrine neoplasms: clinical impact and effectiveness of the available therapeutic options","volume":"110","author":"Merola","year":"2020","journal-title":"Neuroendocrinology."},{"issue":"(12)","key":"2022112511293689000_dgac574-B70","doi-asserted-by":"publisher","first-page":"2754","DOI":"10.1200\/JCO.2005.08.066","article-title":"Radiolabeled somatostatin analog [177Lu-DOTA0, Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors","volume":"23","author":"Kwekkeboom","year":"2005","journal-title":"J Clin Oncol"},{"issue":"(5)","key":"2022112511293689000_dgac574-B71","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1159\/000441604","article-title":"Is there an additional value of using somatostatin receptor subtype 2a immunohistochemistry compared to somatostatin receptor scintigraphy uptake in predicting gastroenteropancreatic neuroendocrine tumor response?","volume":"103","author":"van Adrichem","year":"2016","journal-title":"Neuroendocrinology"},{"issue":"(11)","key":"2022112511293689000_dgac574-B72","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1530\/ERC-20-0340","article-title":"Inferior outcome of neuroendocrine tumor patients negative on somatostatin receptor imaging","volume":"27","author":"Refardt","year":"2020","journal-title":"Endocr Relat Cancer"},{"issue":"(12)","key":"2022112511293689000_dgac574-B73","doi-asserted-by":"publisher","first-page":"4016","DOI":"10.1007\/s00259-021-05359-3","article-title":"Imaging and liquid biopsy in the prediction and evaluation of response to PRRT in neuroendocrine tumors: implications for patient management","volume":"48","author":"Roll","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"(10)","key":"2022112511293689000_dgac574-B74","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.2967\/jnumed.120.256727","article-title":"Quantitative (68)Ga-DOTATATE PET\/CT parameters for the prediction of therapy response in patients with progressive metastatic neuroendocrine tumors treated with (177)Lu-DOTATATE","volume":"62","author":"Ortega","year":"2021","journal-title":"J Nucl Med"},{"issue":"(1)","key":"2022112511293689000_dgac574-B75","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s12022-022-09708-2","article-title":"Overview of the 2022 WHO classification of neuroendocrine neoplasms","volume":"33","author":"Rindi","year":"2022","journal-title":"Endocr Pathol"},{"issue":"(1)","key":"2022112511293689000_dgac574-B76","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s12885-019-6498-z","article-title":"P53, somatostatin receptor 2a and chromogranin A immunostaining as prognostic markers in high grade gastroenteropancreatic neuroendocrine neoplasms","volume":"20","author":"Nielsen","year":"2020","journal-title":"BMC Cancer"},{"issue":"(6)","key":"2022112511293689000_dgac574-B77","doi-asserted-by":"publisher","first-page":"808","DOI":"10.2967\/jnumed.120.244798","article-title":"(18)F-FDG PET is superior to WHO grading as a prognostic tool in neuroendocrine neoplasms and useful in guiding PRRT: a prospective 10-year follow-up study","volume":"62","author":"Binderup","year":"2021","journal-title":"J Nucl Med"},{"issue":"(5)","key":"2022112511293689000_dgac574-B78","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.7150\/thno.18068","article-title":"Dual somatostatin receptor\/FDG PET\/CT imaging in metastatic neuroendocrine tumours: proposal for a novel grading scheme with prognostic significance","volume":"7","author":"Chan","year":"2017","journal-title":"Theranostics"},{"issue":"(9)","key":"2022112511293689000_dgac574-B79","doi-asserted-by":"publisher","first-page":"e431","DOI":"10.1016\/S1470-2045(20)30323-5","article-title":"Molecular profiling of neuroendocrine tumours to predict response and toxicity to peptide receptor radionuclide therapy","volume":"21","author":"Bodei","year":"2020","journal-title":"Lancet Oncol"},{"issue":"(7)","key":"2022112511293689000_dgac574-B80","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1007\/s00259-018-3967-6","article-title":"PRRT genomic signature in blood for prediction of (177)Lu-octreotate efficacy","volume":"45","author":"Bodei","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"(6)","key":"2022112511293689000_dgac574-B81","doi-asserted-by":"publisher","first-page":"e11","DOI":"10.1200\/JOP.2010.000098","article-title":"Multidisciplinary reference centers: the care of neuroendocrine tumors","volume":"6","author":"Singh","year":"2010","journal-title":"J Oncol Pract"},{"key":"2022112511293689000_dgac574-B82","doi-asserted-by":"publisher","DOI":"10.1111\/ecc.13639","article-title":"Evaluation of multidisciplinary team decisions in neuroendocrine neoplasms: impact of expert centres","author":"Zandee","journal-title":"Eur J Cancer Care (Engl)"},{"issue":"(10)","key":"2022112511293689000_dgac574-B83","doi-asserted-by":"publisher","first-page":"2501","DOI":"10.3390\/cancers14102501","article-title":"Clinical management of neuroendocrine neoplasms in clinical practice: a formal consensus exercise","volume":"14","author":"Bartolomei","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"(Suppl 2)","key":"2022112511293689000_dgac574-B84","doi-asserted-by":"publisher","first-page":"61S","DOI":"10.2967\/jnumed.116.186783","article-title":"Somatostatin receptor antagonists for imaging and therapy","volume":"58","author":"Fani","year":"2017","journal-title":"J Nucl Med"},{"issue":"(8)","key":"2022112511293689000_dgac574-B85","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.2967\/jnumed.114.138834","article-title":"Comparison of somatostatin receptor agonist and antagonist for peptide receptor radionuclide therapy: a pilot study","volume":"55","author":"Wild","year":"2014","journal-title":"J Nucl Med"},{"issue":"(13)","key":"2022112511293689000_dgac574-B86","doi-asserted-by":"publisher","first-page":"3047","DOI":"10.1007\/s00259-020-04832-9","article-title":"Comparison of (68)Ga-DOTA-JR11 PET\/CT with dosimetric (177)Lu-satoreotide tetraxetan ((177)Lu-DOTA-JR11) SPECT\/CT in patients with metastatic neuroendocrine tumors undergoing peptide receptor radionuclide therapy","volume":"47","author":"Krebs","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"(11)","key":"2022112511293689000_dgac574-B87","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.2967\/jnumed.120.258889","article-title":"First-in-human study of novel SSTR antagonist (177)Lu-DOTA-LM3 for peptide receptor radionuclide therapy in patients with metastatic neuroendocrine neoplasms: dosimetry, safety and efficacy","volume":"62","author":"Baum","year":"2021","journal-title":"J Nucl Med"},{"issue":"(23)","key":"2022112511293689000_dgac574-B88","doi-asserted-by":"publisher","first-page":"6939","DOI":"10.1158\/1078-0432.CCR-19-1026","article-title":"Phase I trial of well-differentiated neuroendocrine tumors (NETs) with radiolabeled somatostatin antagonist (177)Lu-satoreotide tetraxetan","volume":"25","author":"Reidy-Lagunes","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"(9)","key":"2022112511293689000_dgac574-B89","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.2967\/jnumed.121.263230","article-title":"Targeted alpha-emitter therapy with (212)Pb-DOTAMTATE for the treatment of metastatic SSTR-expressing neuroendocrine tumors: first-in-human, dose-escalation clinical trial","volume":"63","author":"Delpassand","year":"2022","journal-title":"J Nucl Med"},{"issue":"(11)","key":"2022112511293689000_dgac574-B90","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1007\/s00259-014-2857-9","article-title":"\u00b2\u00b9\u00b3Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a first-in-human experience","volume":"41","author":"Kratochwil","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"(2)","key":"2022112511293689000_dgac574-B91","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1053\/j.semnuclmed.2020.02.003","article-title":"Supply and clinical application of Actinium-225 and Bismuth-213","volume":"50","author":"Morgenstern","year":"2020","journal-title":"Semin Nucl Med"},{"issue":"(8)","key":"2022112511293689000_dgac574-B92","doi-asserted-by":"publisher","first-page":"C7","DOI":"10.1530\/ERC-19-0186","article-title":"The next generation of peptide receptor radionuclide therapy","volume":"26","author":"Brabander","year":"2019","journal-title":"Endocr Relat Cancer"},{"key":"2022112511293689000_dgac574-B93","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.122.264043","article-title":"Survival outcomes in metastatic gastroenteropancreatic neuroendocrine tumor patients receiving concomitant (225)Ac-DOTATATE targeted alpha therapy and capecitabine: a real-world scenario management based long-term outcome study","volume":"63","author":"Ballal","year":"2022","journal-title":"J Nucl Med"},{"issue":"(4)","key":"2022112511293689000_dgac574-B94","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1007\/s00259-019-04567-2","article-title":"Broadening horizons with (225)Ac-DOTATATE targeted alpha therapy for gastroenteropancreatic neuroendocrine tumour patients stable or refractory to (177)Lu-DOTATATE PRRT: first clinical experience on the efficacy and safety","volume":"47","author":"Ballal","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"(19)","key":"2022112511293689000_dgac574-B95","doi-asserted-by":"publisher","first-page":"14791","DOI":"10.18632\/oncotarget.9462","article-title":"Epidrug-induced upregulation of functional somatostatin type 2 receptors in human pancreatic neuroendocrine tumor cells","volume":"9","author":"Veenstra","year":"2018","journal-title":"Oncotarget"},{"issue":"(3)","key":"2022112511293689000_dgac574-B96","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s11154-020-09607-z","article-title":"Epigenetic regulation of somatostatin and somatostatin receptors in neuroendocrine tumors and other types of cancer","volume":"22","author":"Klomp","year":"2021","journal-title":"Rev Endocr Metab Disord"},{"issue":"(7)","key":"2022112511293689000_dgac574-B97","doi-asserted-by":"publisher","first-page":"e957","DOI":"10.1002\/ctm2.957","article-title":"Effect of epigenetic treatment on SST(2) expression in neuroendocrine tumour patients","volume":"12","author":"Refardt","year":"2022","journal-title":"Clin Transl Med"},{"issue":"(2)","key":"2022112511293689000_dgac574-B98","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1159\/000362558","article-title":"Hematological toxicity of combined 177Lu-octreotate radiopeptide chemotherapy of gastroenteropancreatic neuroendocrine tumors in long-term follow-up","volume":"99","author":"Kesavan","year":"2014","journal-title":"Neuroendocrinology"},{"issue":"(6)","key":"2022112511293689000_dgac574-B99","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1089\/cbr.2015.1876","article-title":"Neuroendocrine tumor therapy with lutetium-177-octreotate and everolimus (NETTLE): a phase I study","volume":"30","author":"Claringbold","year":"2015","journal-title":"Cancer Biother Radiopharm"},{"issue":"(7)","key":"2022112511293689000_dgac574-B100","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1530\/ERC-21-0082","article-title":"Long-term hematologic toxicity of 177Lu-octreotate\u2013capecitabine\u2013temozolomide therapy of GEPNET","volume":"28","author":"Kesavan","year":"2021","journal-title":"Endocr Relat Cancer"},{"issue":"(4 Suppl)","key":"2022112511293689000_dgac574-B101","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1200\/JCO.2020.38.4_suppl.604","article-title":"First results for Australasian Gastrointestinal Trials Group (AGITG) control net study: phase II study of 177Lu-octreotate peptide receptor radionuclide therapy (LuTate PRRT) +\/- capecitabine, temozolomide (CAPTEM) for midgut neuroendocrine tumors (mNETs)","volume":"38","author":"Pavlakis","year":"2020","journal-title":"J Clin Oncol"},{"issue":"11","key":"2022112511293689000_dgac574-B102","doi-asserted-by":"publisher","first-page":"e457","DOI":"10.1097\/RLU.0000000000001816","article-title":"Concomitant 177Lu-DOTATATE and capecitabine therapy in patients with advanced neuroendocrine tumors: a long-term-outcome, toxicity, survival, and quality-of-life study","volume":"42","author":"Ballal","year":"2017","journal-title":"Clin Nucl Med"},{"key":"2022112511293689000_dgac574-B103","doi-asserted-by":"publisher","first-page":"481279","DOI":"10.1155\/2015\/481279","article-title":"Theranostic imaging of yttrium-90","volume":"2015","author":"Wright","year":"2015","journal-title":"Biomed Res Int"},{"issue":"(Suppl 1)","key":"2022112511293689000_dgac574-B104","first-page":"83S","article-title":"Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0), Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate","volume":"46","author":"Valkema","year":"2005","journal-title":"J Nucl Med"},{"issue":"(10)","key":"2022112511293689000_dgac574-B105","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1200\/JCO.2009.22.8585","article-title":"90Y-edotreotide for metastatic carcinoid refractory to octreotide","volume":"28","author":"Bushnell","year":"2010","journal-title":"J Clin Oncol"},{"issue":"(24)","key":"2022112511293689000_dgac574-B106","doi-asserted-by":"publisher","first-page":"16932","DOI":"10.18632\/oncotarget.24524","article-title":"Results and adverse events of personalized peptide receptor radionuclide therapy with (90)yttrium and (177)lutetium in 1048 patients with neuroendocrine neoplasms","volume":"9","author":"Baum","year":"2018","journal-title":"Oncotarget"},{"issue":"(1)","key":"2022112511293689000_dgac574-B107","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s12876-018-0817-8","article-title":"Additional hepatic (166)Ho-radioembolization in patients with neuroendocrine tumours treated with (177)Lu-DOTATATE; a single center, interventional, non-randomized, non-comparative, open label, phase II study (HEPAR PLUS trial)","volume":"18","author":"Braat","year":"2018","journal-title":"BMC Gastroenterol"},{"issue":"(1)","key":"2022112511293689000_dgac574-B108","doi-asserted-by":"publisher","first-page":"173","DOI":"10.3390\/pharmaceutics14010173","article-title":"The effect of VPA treatment on radiolabeled DOTATATE uptake: differences observed in vitro and in vivo","volume":"14","author":"Klomp","year":"2022","journal-title":"Pharmaceutics"},{"issue":"(1)","key":"2022112511293689000_dgac574-B109","doi-asserted-by":"publisher","first-page":"10196","DOI":"10.1038\/s41598-020-67199-9","article-title":"Enhancing the anti-tumour activity of (177)Lu-DOTA-octreotate radionuclide therapy in somatostatin receptor-2 expressing tumour models by targeting PARP","volume":"10","author":"Cullinane","year":"2020","journal-title":"Sci Rep"},{"issue":"(19)","key":"2022112511293689000_dgac574-B110","doi-asserted-by":"publisher","first-page":"4905","DOI":"10.3390\/cancers13194905","article-title":"Comparing the effect of multiple histone deacetylase inhibitors on SSTR2 expression and [(111)In]In-DOTATATE uptake in NET cells","volume":"13","author":"Klomp","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"(1)","key":"2022112511293689000_dgac574-B111","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s13063-019-3888-0","article-title":"Intra-arterial versus standard intravenous administration of lutetium-177-DOTA-octreotate in patients with NET liver metastases: study protocol for a multicenter, randomized controlled trial (LUTIA trial)","volume":"21","author":"Ebbers","year":"2020","journal-title":"Trials"},{"issue":"(1126)","key":"2022112511293689000_dgac574-B112","doi-asserted-by":"publisher","first-page":"20210403","DOI":"10.1259\/bjr.20210403","article-title":"Dosimetric analyses of intra-arterial versus standard intravenous administration of 177Lu-DOTATATE in patients of well differentiated neuroendocrine tumor with liver-dominant metastatic disease","volume":"94","author":"Thakral","year":"2021","journal-title":"Br J Radiol"},{"issue":"(Suppl 15)","key":"2022112511293689000_dgac574-B113","first-page":"LBA4","article-title":"Phase III study of lutetium-177-PSMA-617 in patients with metastatic castration-resistant prostate cancer (VISION)","volume":"39","author":"Morris","year":"2021","journal-title":"Clin Oncol"},{"issue":"(10276)","key":"2022112511293689000_dgac574-B114","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","article-title":"[(177)Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial","volume":"397","author":"Hofman","year":"2021","journal-title":"Lancet"},{"issue":"(2)","key":"2022112511293689000_dgac574-B115","doi-asserted-by":"publisher","first-page":"293","DOI":"10.2967\/jnumed.116.176636","article-title":"68Ga\/177Lu-NeoBOMB1, a novel radiolabeled GRPR antagonist for theranostic use in oncology","volume":"58","author":"Dalm","year":"2017","journal-title":"J Nucl Med"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgac574\/46596131\/dgac574.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/107\/12\/3199\/47260118\/dgac574.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/107\/12\/3199\/47260118\/dgac574.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T12:24:18Z","timestamp":1669379058000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/107\/12\/3199\/6748972"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,5]]},"references-count":115,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2022,10,5]]},"published-print":{"date-parts":[[2022,11,25]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgac574","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,12,1]]},"published":{"date-parts":[[2022,10,5]]}}}